Experience of the use of insulin degludec in the treatment of patients with type 1 diabetes mellitus (according to the data of the Moscow segment of the Federal Diabetes Register)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. The basis of modern therapy for type 1 diabetes mellitus (DM1) is the replenishment of the basal and prandial insulin secretion. Introduction into clinical practice of new drugs with a profile of action similar to the physiological insulin action is an extremely important task. The beginning of the use of basal, non-peak long-acting insulin analogs in clinical practice opened the way to ensure adequate glycemic control at night with minimal risk of hypoglycemic states. A new drug of this class, insulin degludec, has demonstrated new possibilities for effectively controlling the glycated hemoglobin (HbA1c) level, reducing glycemic variability and ensuring a low risk of general, nocturnal and severe hypoglycemia compared to other basal insulins. Objective. Evaluation of the glycemic control parameters in patients with type 1 diabetes mellitus receiving insulin degludec. Methods. On the basis of the Moscow segment of the Federal Diabetes register, a sample of patients with type 1 diabetes receiving therapy with insulin deludec since 2016 (n=178) was formed. A statistical analysis of the patient data was conducted: age and sex, the average HbA1c level, the average dose of basal and prandial insulin before insulin degludec administration, and the dynamics of these indicators for 3 years was analyzed. Results. A statistically significant decrease in HbA1с level by 0.6% (from 8.2 to 7.6%) in the period from 2015 to 2016 inclusive (the period of transferring patients to the therapy with insulin degludec) and stable retention of HbA1c at a level of 7.4 % in the next 2 years was revealed. A statistically significant decrease in the average total dose of insulin by 0.04 U/kg (from 0.88 to 0.84 U/kg) due to a decrease in the dose of basal insulin by 0.03 U/kg was observed (p<0.05). At the same time, there was a non-significant tendency to a decrease in the dose of prandial insulin. Conclusion. The transfer of DM1 patients to insulin degludec leads to a statistically significant decrease in HbA1c level. The achieved reduction in HbA1c level persists for at least 2 years. The transfer of DM1 patients to insulin degludec is accompanied by a statistically significant reduction in the dose of basal insulin, while there is no statistically significant change in the dose of prandial insulin.

Full Text

Restricted Access

About the authors

Nikolai A. Demidov

Hospital in Moskovsky town of the Moscow Healthcare Department

Email: nicolay13@mail.ru
PhD, Endocrinologist Moscow, Russia

O. A Mishra

City Outpatient Clinic № 5 of the Moscow Healthcare Department

Moscow, Russia

M. B Antsiferov

Endocrinological Dispensary of the Moscow Healthcare Department

Moscow, Russia

References

  1. Дедов И.И., Шестакова М.В., Викулова О.К. и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г Сахарный диабет. 2018;21(3):144-59. doi: 10.14341/DM9686.
  2. Демидов Н.А., Мишра О.А., Анциферов М.Б. Сахарный диабет 1 типа в Москве - 2018 г (по данным Московского сегмента Федерального регистра сахарного диабета). Фарматека. 2018;11:74-8. Doi: https://dx.doi. org/10.18565/pharmateca.2018.11.74-8.
  3. Heise T., Hermanski L., Nosek L., et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabet Obes Metab. 2012;14:859-64.
  4. Heise T., Hovelmann U., Nosek L., et al. Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine (Abstract). Diabetol. 2011; 54:5425.
  5. Kurtzhals P., Heise T., Strauss H.M., et al. Multihexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec (Abstract). Diabetol. 2011;54:5426.
  6. Heise T., Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabet Obes Metab. 2017;19:3-12
  7. Инструкция по применению препарата Тресиба® ФлексТач®. Доступно на: http://grls.rosminzdrav. ru [Instructions for use of the drug Tresiba® FlexTach®. Available at: http://grls.rosminzdrav.ru (In Russ.)].
  8. Ratner R.E., Gough S.C., Mathieu C., et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabet Obes Metab. 2013;15:175-84.
  9. Marso S.P., McGuire D.K., Zinman B., et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N. Engl. J. Med. 2017;377:723-32.
  10. Siegmund T., Tentolouris N., Knudsen S.T., et al. A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes. Diabet Obes Metab. 2018;20:689-97. doi: 10.1111/dom.13149.
  11. Демидов Н.А., Котешкова О.М., Пашкова Е.Ю., Мишра О.А. Использование инсулинового дозатора Акку-чек Спирит Комбо в терапии больных сахарным диабетом 1-го типа. Consilium Medicum. 2018;20(12):128-34. doi: 10.26442/20751753.2018.12.180140.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies